Skip to main content

Table 1 Demographic and clinical characteristics of patients in the University of North Carolina Center for AIDS Research HIV Clinical Cohort, stratified by calendar year intervals 2000-2011

From: Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011

Characteristic N (%) 2000-2002 2003-2005 2006-2008 2009-2011 Total P*
Total 1866 1849 1843 1767 3141  
Female sex 598 (31.8) 601 (32.3) 544 (29.3) 514 (28.4) 932 (29.7) 0.03
Race       
Black 1136 (61.0) 1088 (58.9) 1047 (57.0) 997 (56.4) 1862 (59.3)  
White 591 (31.7) 610 (33.0) 596 (32.3) 563 (31.9) 962 (30.6)  
Other 142 (7.5) 153 (8.2) 202 (10.9) 207 (11.7) 317 (10.1) <0.01
MSM 566 (30.3) 623 (33.6) 640 (34.6) 516 (29.2) 889 (28.3) <0.01
IDU 261 (14.0) 248 (13.4) 208 (11.2) 152 (8.6) 340 (10.8) <0.01
Age (years) 40 (34–46) 42 (36–49) 44 (37–51) 46 (38–52) 43 (36–50) <0.01
CD4 cell count (cells/mm3) 376 (181–602) 403 (218–621) 440 (251–657) 519 (335–737) 440 (244–660) <0.01
HIV RNA (log10 copies/ml) 2.92 (2.30-4.47) 2.73 (BLD-4.45) 2.05 (BLD-4.05) BLD (BLD-2.58) 2.37 (BLD-4.11) <0.01
ART experience (person-years after ART exposure) 3322 (81.6) 3505 (83.7) 3680 (83.8) 3871 (88.0) 14378 (84.3) <0.01
  1. *P-values from Chi-squared test for categorical and binary characteristics, and Kruskal-Willis test for continuous characteristics. Undetectable HIV RNA results were assigned a value of half the limit of detection for the purposes of assessing trends across time.
  2. Median (Interquartile Range) presented for continuous characteristics.
  3. The number of years of follow-up within the time interval contributed by ART-experienced patients and the percentage of all follow-up within the time interval that was contributed be ART-experienced patients.
  4. BLD: below limit of detection (<50 copies/mL); ART: antiretroviral therapy; MSM: men who have sex with men; IDU: injection drug user.